Cerulean raises $24 million series C to fund nanodrug pipeline
This article was originally published in Scrip
Executive Summary
Nanopharmaceuticals-focused Cerulean Pharma has closed a $24 million series C financing led by new investor Lilly Ventures. All existing investors, including Polaris Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners, also participated. The company plans to use the financing proceeds to advance its